Lu to Present Overview of Company’s Novel RNAi Technology Platform
GAITHERSBURG, Md., Oct. 9, 2019 /PRNewswire/ -- Sirnaomics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that President and CEO Patrick Lu, PhD, is scheduled to deliver the keynote address at the RNAi China conference on October 10 at 11:05 AM Beijing Time. In a presentation titled “Novel siRNA Therapeutics for Enhancing Antitumor Activity of Immune Checkpoint Inhibitor”, Dr. Lu plans to share an overview of Sirnaomics’ differentiated RNAi technology platform, which leverages its proprietary polypeptide nanoparticle (PNP) drug delivery system to optimize the delivery of siRNA drugs into the tumor microenvironment and an array of liver cell types implicated in the progression of liver cancer and liver fibrosis. Sirnaomics’ STP705 currently is being evaluated in Phase 2 clinical trials for treatment of non-melanoma skin cancer and has received Orphan Drug Designation from the US FDA for liver cancer and liver fibrosis. About Sirnaomics, Inc. CONTACT: Westwicke Healthcare Media: James Heins View original content:http://www.prnewswire.com/news-releases/sirnaomics-president-and-ceo-patrick-lu-to-give-keynote-address-at-rnai-china-conference-300934815.html SOURCE Sirnaomics, Inc. |